Pathology of Alcoholic and Nonalcoholic Fatty Liver Disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-319-20538-0_12
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease

  2014cited by this paper
• Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion.

  2014cited by this paper
• Hepatic Pathology among Patients without Known Liver Disease Undergoing Bariatric Surgery: Observations and a Perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) Study

  2014cited by this paper
• Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease

  2014cited by this paper
• Drug-Induced Hepatic Steatosis

  2014cited by this paper
• A histologic scoring system for prognosis of patients with alcoholic hepatitis.

  2014cited by this paper
• Liver transplantation in alcoholic liver disease current status and controversies.

  2013cited by this paper
• The liver diseases of lipodystrophy: the long-term effect of leptin treatment.

  2013cited by this paper
• Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.

  2013cited by this paper
• A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.

  2013cited by this paper
• PNPLA3 I148M polymorphism and progressive liver disease.

  2013cited by this paper
• Primary Biliary Cirrhosis is More Severe in Overweight Patients

  2013cited by this paper
• Prevalence and natural history of alcoholic liver disease.

  2012cited by this paper
• Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease.

  2012cited by this paper
• Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients

  2012cited by this paper
• EASL clinical practical guidelines: management of alcoholic liver disease.

  2012cited by this paper
• Nonalcoholic Fatty Liver Disease and HIV Infection

  2012cited by this paper
• Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research

  2012cited by this paper
• The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis.

  2011cited by this paper
• Histopathological evaluation of fatty and alcoholic liver diseases

  2011cited by this paper
• Endpoints and clinical trial design for nonalcoholic steatohepatitis

  2011cited by this paper
• Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease

  2011cited by this paper
• Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease.

  2011cited by this paper
• Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

  2011cited by this paper
• Early liver biopsy, intraparenchymal cholestasis, and prognosis in patients with alcoholic steatohepatitis

  2011cited by this paper
• The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis

  2011cited by this paper
• Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data

  2010cited by this paper
• Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease

  2010cited by this paper
• Predicting Fibrosis Worsening in Obese Patients With NASH Through Parenchymal Fibronectin, HOMA-IR, and Hypertension

  2010cited by this paper
• Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study

  2010cited by this paper
• Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

  2010cited by this paper
• Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors.

  2010cited by this paper
• Biliary intraepithelial neoplasia in patients without chronic biliary disease

  2009cited by this paper
• Weight effects associated with antipsychotics: a comprehensive database analysis.

  2009cited by this paper
• Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis.

  2009cited by this paper
• NASH and cryptogenic cirrhosis: a histological analysis.

  2009cited by this paper
• Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease.

  2009cited by this paper
• Toward unraveling the complexity of simple epithelial keratins in human disease.

  2009cited by this paper
• Lipogranulomas in human liver biopsies with fatty change. A morphological, biochemical and clinical investigation.

  2009cited by this paper
• Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD—Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network

  2009cited by this paper
• Gastrointestinal , Hepatobiliary and Pancreatic Pathology Increased Hepatic Myeloperoxidase Activity in Obese Subjects with Nonalcoholic Steatohepatitis

  2009cited by this paper
• Portal tract lipogranulomas in liver biopsies.

  2008cited by this paper
• Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis.

  2008cited by this paper
• Porphyria cutanea tarda and liver disease. A retrospective analysis of 17 cases from a single centre and review of the literature.

  2008cited by this paper
• Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis.

  2008cited by this paper
• Epithelial–mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease

  2008cited by this paper
• A New Scoring System for Prognostic Stratification of Patients With Alcoholic Hepatitis

  2008cited by this paper
• Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.

  2008cited by this paper
• Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.

  2008cited by this paper
• Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease.

  2008cited by this paper
• Management strategies in alcoholic liver disease

  2007cited by this paper
• Spectrum of Liver Histology in Presumed Decompensated Alcoholic Liver Disease

  2007cited by this paper
• Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C.

  2007cited by this paper
• Transjugular liver biopsy--indications, adequacy, quality of specimens, and complications--a systematic review.

  2007cited by this paper
• Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features

  2007cited by this paper
• Influence of Liver Biopsy Heterogeneity and Diagnosis of Nonalcoholic Steatohepatitis in Subjects Undergoing Gastric Bypass

  2007cited by this paper
• Conversion of Micronodular Cirrhosis into Macronodular Cirrhosis

  2007cited by this paper
• Iron overload syndromes and the liver

  2007cited by this paper
• HFE gene in primary and secondary hepatic iron overload.

  2007cited by this paper
• Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass.

  2007cited by this paper
• Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis

  2006cited by this paper
• Glycogenic Hepatopathy: An Underrecognized Hepatic Complication of Diabetes Mellitus

  2006cited by this paper
• Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease.

  2006cited by this paper
• The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: an update.

  2006cited by this paper
• A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

  2006cited by this paper
• In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease

  2006cited by this paper
• Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection

  2006cited by this paper
• Preneoplastic lesions in human hepatocarcinogenesis

  2005cited by this paper
• Histopathology of pediatric nonalcoholic fatty liver disease

  2005cited by this paper
• Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy

  2005cited by this paper
• Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score

  2005cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Proposal for a histological scoring and grading system for non‐alcoholic fatty liver disease

  2005cited by this paper
• Iron accumulation in alcoholic liver diseases.

  2005cited by this paper
• Sampling variability of liver biopsy in nonalcoholic fatty liver disease.

  2005cited by this paper
• Histological characteristics and prognosis in patients with fatty liver

  2005cited by this paper
• Coarse vs. fine needle aspiration biopsy for the assessment of diffuse liver disease from hepatitis C virus-related chronic hepatitis.

  2004cited by this paper
• Hepatocellular carcinoma in cirrhosis: incidence and risk factors.

  2004cited by this paper
• Low‐grade steatosis and major changes in portal flow as new prognostic factors in steroid‐treated alcoholic hepatitis

  2004cited by this paper
• A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

  2004cited by this paper
• Alcohol and hepatocellular carcinoma.

  2004cited by this paper
• Acquired and inherited lipodystrophies.

  2004cited by this paper
• Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial

  2004cited by this paper
• Hepatitis C and nonalcoholic fatty liver disease.

  2004cited by this paper
• Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis.

  2003cited by this paper
• Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome

  2003cited by this paper
• Risperidone-associated Steatohepatitis and Excessive Weight-gain

  2003cited by this paper
• Sampling variability of liver fibrosis in chronic hepatitis C

  2003cited by this paper
• Concurrence of Histologic Features of Steatohepatitis with Other Forms of Chronic Liver Disease

  2003cited by this paper
• HIV-associated lipodystrophy syndrome: description and pathogenesis.

  2003cited by this paper
• Respective roles of porto‐septal fibrosis and centrilobular fibrosis in alcoholic liver disease

  2003cited by this paper
• Portal lymphocytic infiltrate in alcoholic liver disease.

  2002cited by this paper
• Kriging Water Levels with a Regional‐Linear and Point‐Logarithmic Drift

  2002cited by this paper
• Leptin-replacement therapy for lipodystrophy.

  2002cited by this paper
• Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol

  2002cited by this paper
• Kupffer Cell Aggregation and Perivenular Distribution in Steatohepatitis

  2002cited by this paper
• Pathology of steatohepatitis.

  2002cited by this paper
• Nonalcoholic Steatohepatitis: Definition and Pathology

  2001cited by this paper
• Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis

  2001cited by this paper
• Hepatic steatosis in chronic hepatitis C virus infection: Prevalence and clinical correlation

  2001cited by this paper

• Hepatocellular carcinoma—An updated review

  2022cites this paper
• Inhibition of miR-499-5p expression improves nonalcoholic fatty liver disease.

  2019cites this paper
• Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury

  2017cites this paper
• Clinical Trial Design for Alcoholic Hepatitis

  2017cites this paper